Bellecapital International Ltd. Buys 13,491 Shares of Pfizer Inc. (NYSE:PFE)

Bellecapital International Ltd. boosted its stake in shares of Pfizer Inc. (NYSE:PFEFree Report) by 41.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 46,123 shares of the biopharmaceutical company’s stock after buying an additional 13,491 shares during the period. Bellecapital International Ltd.’s holdings in Pfizer were worth $1,328,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in PFE. Argus Investors Counsel Inc. increased its holdings in shares of Pfizer by 17.2% in the 4th quarter. Argus Investors Counsel Inc. now owns 43,315 shares of the biopharmaceutical company’s stock worth $1,247,000 after purchasing an additional 6,350 shares in the last quarter. Caldwell Sutter Capital Inc. increased its holdings in shares of Pfizer by 3.1% in the 4th quarter. Caldwell Sutter Capital Inc. now owns 71,947 shares of the biopharmaceutical company’s stock worth $2,071,000 after purchasing an additional 2,153 shares in the last quarter. Foster Victor Wealth Advisors LLC increased its holdings in shares of Pfizer by 23.9% in the 4th quarter. Foster Victor Wealth Advisors LLC now owns 365,955 shares of the biopharmaceutical company’s stock worth $10,825,000 after purchasing an additional 70,523 shares in the last quarter. Mirador Capital Partners LP increased its holdings in shares of Pfizer by 6.6% in the 4th quarter. Mirador Capital Partners LP now owns 81,647 shares of the biopharmaceutical company’s stock worth $2,351,000 after purchasing an additional 5,084 shares in the last quarter. Finally, Denali Advisors LLC boosted its stake in shares of Pfizer by 11.1% in the 4th quarter. Denali Advisors LLC now owns 26,100 shares of the biopharmaceutical company’s stock worth $751,000 after buying an additional 2,600 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 0.1 %

Shares of PFE stock opened at $27.75 on Monday. Pfizer Inc. has a 1 year low of $25.61 and a 1 year high of $42.22. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The stock’s 50 day simple moving average is $27.44 and its two-hundred day simple moving average is $29.37. The company has a market cap of $157.14 billion, a PE ratio of 77.08, a price-to-earnings-growth ratio of 1.24 and a beta of 0.61.

Pfizer (NYSE:PFEGet Free Report) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. During the same period in the prior year, the business posted $1.14 earnings per share. The company’s quarterly revenue was down 41.3% compared to the same quarter last year. Research analysts predict that Pfizer Inc. will post 2.22 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on PFE shares. Barclays dropped their price target on Pfizer from $34.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Thursday, December 14th. Truist Financial lowered their target price on Pfizer from $42.00 to $36.00 and set a “buy” rating on the stock in a research report on Thursday, December 14th. Guggenheim initiated coverage on Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research report on Thursday, January 4th. Finally, Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Twelve investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $36.88.

View Our Latest Research Report on Pfizer

About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Articles

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.